Skip to content

Israel’s medical cannabis patient count falls from an August record

142,000 patients in September, after 145,700 in August • Imports hit 6.69 tons, then fell to 728 kilograms

As of September 2026, the number of medical-cannabis patients in Israel stands at 142,000, according to the «situation report» of the Israel Medical Cannabis Agency (IMCA, known in Hebrew as יק״ר, the medical cannabis unit at the Ministry of Health) for September 2026, published on 11 November 2026. According to the data series in the report, that is a decline of about 3,700 patients from a peak of 145,700 recorded in August. In June and July the figure stood at 143,700. Compared with September 2025 (135,300), there is still an annual addition of about 6,700 patients.

The previous monthly report IMCA published was for June, but the data series in the September report also includes July and August. In the last article in this series, on the May figures, the magazine had still reported a return to an upward trend. After the August peak, the September figures reversed the trend.

Licences are falling, and prescriptions did not cover the drop

Of all those eligible, 107,474 hold an active licence and about 34,500 others receive a prescription through the health funds (Kupot Holim). The share of prescription holders reaches about 24% of all patients. The licence roster fell from 112,449 in June to 107,474 in September, a drop of 4,975 active licences. In the same period the number of prescription recipients rose from about 31,300 to about 34,500, but they too retreated from a peak of about 36,600 in August. The September decline was therefore recorded on both tracks, and the growth in prescriptions since June does not cover the decline in licences.

The September report’s series (page 3 of the report) gives total patients; the split follows the licence figure on page 2 (prescriptions = the total minus licences; the total is rounded to hundreds). Some months in 2025 are empty because no report was published. Source: IMCA «situation reports», Ministry of Health.

Accordingly, the monthly entitlement quantity of licence holders also fell, to 4,401 kilograms in September, compared with 4,558 kilograms in June, of which 4,194 kilograms were in flower and 186 kilograms in extract. The utilization rate in pharmacies stood at 89% in September, and at 88% on average over the last six months (April–September). In that period 23,774.9 kilograms were used out of 26,925.7 kilograms approved in licences.

Pain still leads, and every health fund recorded a decline

The indication of chronic and neuropathic pain remains dominant, with 75,079 licences, down from 78,657 in June. After it, by a wide gap, is psychiatry–PTSD with 21,210 licences, down from 21,841 in June. The «other» heading stands at 11,430. These numbers do not necessarily add up to 107,474, because one licence may have more than one indication.

By gender among licence holders: 70,296 men and 37,177 women. Among the health funds, Clalit continues to lead with 52,330 licences, followed by Maccabi (31,264), Leumit (9,156), Meuhedet (9,097) and 5,627 in other frameworks. Every health fund recorded a decline compared with June, and Leumit slightly overtook Meuhedet.

A record import month in August, and a slump in September

Foreign trade was the sharper story this time. In August, 6.69 tons of medical cannabis were imported into Israel, a new monthly record, passing the previous record from August 2025 (6.49 tons). A month later, in September, imports dropped to only 728 kilograms.

Exports also contracted: from 2.56 tons in May and 1.57 tons in July, they fell to 348 kilograms in August and 141 kilograms in September. From the beginning of 2026 through September, about 22.75 tons were imported and about 8.60 tons were exported.

In the 12 months covered by the IMCA chart (October 2025 to September 2026), total imports were 31.9 tons and total exports 11.9 tons. Imports were 2.7 times larger than exports. No import was reported in IMCA’s figures for January 2026. Source: the situation report for September 2026, page 11.

This volatility continues a familiar pattern of large import months alongside thin ones, against the background of the anti-dumping investigation at the Ministry of Economy. The IMCA report does not specify the country of origin.

What this means for the industry

After months in which it had appeared that the market was returning to growth, the September report presents the opposite picture: fewer licences, a smaller monthly entitlement, and the overall customer base retreating from the August peak. The prescription track has grown since June, but it retreated from the August peak and does not compensate for the decline in licences. For local growers the picture is also complicated from the supply side: August brought a record import month, and September fell to a low of 728 kilograms, volatility that makes it hard to plan stock and price, exactly as the argument over an anti-dumping levy continues.

Compared with September a year earlier there are still more patients in the system, but relative to the August peak the direction has changed. The figures for the coming months will determine whether this is a one-off correction or a change in trend.

The full report for September 2026 is in the Cannabiz information centre (Hebrew).

Enjoyed this article? Add us on GoogleTo see more from Cannabis Magazine in your search results (opens in new tab)